180 related articles for article (PubMed ID: 31355956)
1. Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis.
Lee DG; Lee HJ; Yan JL; Lin SS; Aram JA
Mycoses; 2019 Oct; 62(10):969-978. PubMed ID: 31355956
[TBL] [Abstract][Full Text] [Related]
2. Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA; Schlamm HT; Herbrecht R; Rottinghaus ST; Bow EJ; Cornely OA; Heinz WJ; Jagannatha S; Koh LP; Kontoyiannis DP; Lee DG; Nucci M; Pappas PG; Slavin MA; Queiroz-Telles F; Selleslag D; Walsh TJ; Wingard JR; Maertens JA
Ann Intern Med; 2015 Jan; 162(2):81-9. PubMed ID: 25599346
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4727-36. PubMed ID: 24914120
[TBL] [Abstract][Full Text] [Related]
5. Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies.
Dib RW; Hachem RY; Chaftari AM; Ghaly F; Jiang Y; Raad I
BMC Infect Dis; 2018 Dec; 18(1):656. PubMed ID: 30545320
[TBL] [Abstract][Full Text] [Related]
6. Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.
Jin J; Wu D; Liu Y; Pan S; Yan JL; Aram JA; Lou YJ; Meng H; Chen X; Zhang X; Schwartz IS; Patterson TF
BMC Infect Dis; 2019 May; 19(1):471. PubMed ID: 31138134
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA; Rahav G; Lee DG; Ponce-de-León A; Ramírez Sánchez IC; Klimko N; Sonet A; Haider S; Diego Vélez J; Raad I; Koh LP; Karthaus M; Zhou J; Ben-Ami R; Motyl MR; Han S; Grandhi A; Waskin H;
Lancet; 2021 Feb; 397(10273):499-509. PubMed ID: 33549194
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.
Liu P; Mould DR
Antimicrob Agents Chemother; 2014 Aug; 58(8):4718-26. PubMed ID: 24913161
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study.
Lestrade PP; Bentvelsen RG; Schauwvlieghe AFAD; Schalekamp S; van der Velden WJFM; Kuiper EJ; van Paassen J; van der Hoven B; van der Lee HA; Melchers WJG; de Haan AF; van der Hoeven HL; Rijnders BJA; van der Beek MT; Verweij PE
Clin Infect Dis; 2019 Apr; 68(9):1463-1471. PubMed ID: 30307492
[TBL] [Abstract][Full Text] [Related]
11. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
[TBL] [Abstract][Full Text] [Related]
12. Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.
Herbrecht R; Patterson TF; Slavin MA; Marchetti O; Maertens J; Johnson EM; Schlamm HT; Donnelly JP; Pappas PG
Clin Infect Dis; 2015 Mar; 60(5):713-20. PubMed ID: 25414266
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole-refractory invasive aspergillosis.
Park SY; Yoon JA; Kim SH
Korean J Intern Med; 2017 Sep; 32(5):805-812. PubMed ID: 28835093
[TBL] [Abstract][Full Text] [Related]
15. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
Ruhnke M; Paiva JA; Meersseman W; Pachl J; Grigoras I; Sganga G; Menichetti F; Montravers P; Auzinger G; Dimopoulos G; Borges Sá M; Miller PJ; Marček T; Kantecki M
Clin Microbiol Infect; 2012 Jul; 18(7):680-7. PubMed ID: 22404732
[TBL] [Abstract][Full Text] [Related]
16. Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.
Martin JM; Macias-Parra M; Mudry P; Conte U; Yan JL; Liu P; Capparella MR; Aram JA
Pediatr Infect Dis J; 2017 Jan; 36(1):e1-e13. PubMed ID: 27636722
[TBL] [Abstract][Full Text] [Related]
17. Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes.
Dandachi D; Wilson Dib R; Fernández-Cruz A; Jiang Y; Chaftari AM; Hachem R; Raad I
Ann Med; 2018 Dec; 50(8):713-720. PubMed ID: 30230385
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.
Resendiz-Sharpe A; Mercier T; Lestrade PPA; van der Beek MT; von dem Borne PA; Cornelissen JJ; De Kort E; Rijnders BJA; Schauwvlieghe AFAD; Verweij PE; Maertens J; Lagrou K
J Antimicrob Chemother; 2019 Sep; 74(9):2759-2766. PubMed ID: 31236587
[TBL] [Abstract][Full Text] [Related]
20. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
